Jeffrey J Tarrand
Overview
Explore the profile of Jeffrey J Tarrand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1315
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wurster S, Paraskevopoulos T, Toda M, Jiang Y, Tarrand J, Williams S, et al.
J Infect
. 2022 Mar;
84(5):701-709.
PMID: 35288118
Objectives: Extensive floodwater damage following hurricane Harvey raised concerns of increase in invasive mould infections (IMIs), especially in immunocompromised patients. To more comprehensively characterize the IMI landscape pre- and post-Harvey,...
2.
Wurster S, Albert N, Bharadwaj U, Kasembeli M, Tarrand J, Daver N, et al.
Front Immunol
. 2022 Mar;
13:838344.
PMID: 35251033
Anecdotal clinical reports suggested a benefit of adjunct immune checkpoint inhibitors (ICIs) to treat invasive mucormycosis. However, proof-of-concept data in animal models and mechanistic insights into the effects of ICIs...
3.
Mori N, Szvalb A, Adachi J, Tarrand J, Mulanovich V
BMC Infect Dis
. 2021 Sep;
21(1):1021.
PMID: 34587893
Background: Non-typhoidal Salmonella (NTS) infection is thought to be more severe in cancer patients, but this has not been studied since the development of new cancer therapies, increasing antibiotic resistance...
4.
Axell-House D, Wurster S, Jiang Y, Kyvernitakis A, Lewis R, Tarrand J, et al.
J Fungi (Basel)
. 2021 Apr;
7(3).
PMID: 33802827
Although breakthrough mucormycosis (BT-MCR) is known to develop on mold-active antifungals without Mucorales activity, it can also occur while on Mucorales-active antifungals. Herein, we retrospectively compared the characteristics and outcomes...
5.
Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson B, Martinez C, et al.
Transpl Infect Dis
. 2020 Jul;
22(5):e13395.
PMID: 32602954
Background: BK polymavirus (BKPyV), a member of the family Polyomaviridae, is associated with increased morbidity and mortality in allogeneic stem cell transplant recipients. Methods: In our previous retrospective study of...
6.
Wurster S, Robinson P, Albert N, Tarrand J, Goff M, Swamydas M, et al.
J Infect Dis
. 2020 May;
222(6):989-994.
PMID: 32432714
Pharmacological immune checkpoint blockade has revolutionized oncological therapies, and its remarkable success has sparked interest in expanding checkpoint inhibitor therapy in infectious diseases. Herein, we evaluated the efficacy of programmed...
7.
Benanti G, Brown A, Shigle T, Tarrand J, Bhatti M, McDaneld P, et al.
Antimicrob Agents Chemother
. 2018 Dec;
63(2).
PMID: 30509935
Infections with extended-spectrum-β-lactamase (ESBL)-producing are common in patients with hematologic malignancy. The utility of cefepime and piperacillin-tazobactam as empiric therapy for ESBL-producing bacteremia in patients with hematologic malignancy is largely...
8.
Folan S, Marx K, Tverdek F, Raad I, Mulanovich V, Tarrand J, et al.
Open Forum Infect Dis
. 2018 Aug;
5(7):ofy167.
PMID: 30090838
Background: Coagulase-negative staphylococci, including , are the most common cause of bloodstream infection in cancer patients. Linezolid resistance is increasingly identified in but whether such resistance alters the clinical course...
9.
Szvalb A, Rolston K, Mori N, Tarrand J, Mulanovich V
J Infect
. 2018 Jul;
78(1):48-53.
PMID: 30048653
Objective: To investigate the clinical manifestations, microbiological data, and outcomes of Bordetella bronchiseptica (Bb) infections in patients with cancer. Methods: Review of electronic medical records of 24 patients with Bb...
10.
Liu J, Mouhayar E, Tarrand J, Kontoyiannis D
Mycoses
. 2017 Dec;
61(4):245-255.
PMID: 29280197
Cryptococcus neoformans is a saprophytic fungal pathogen that can cause serious illness in immune-compromised hosts and it presents with a wide variety of clinical symptoms. We present a fatal case...